IN2012DN01981A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01981A
IN2012DN01981A IN1981DEN2012A IN2012DN01981A IN 2012DN01981 A IN2012DN01981 A IN 2012DN01981A IN 1981DEN2012 A IN1981DEN2012 A IN 1981DEN2012A IN 2012DN01981 A IN2012DN01981 A IN 2012DN01981A
Authority
IN
India
Prior art keywords
rgd
disease
diseases
proteins
granuloma
Prior art date
Application number
Other languages
English (en)
Inventor
Shankar Kumar
J Yun Tso
Naoya Tsurushita
Original Assignee
Gene Techno Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Techno Science Co Ltd filed Critical Gene Techno Science Co Ltd
Publication of IN2012DN01981A publication Critical patent/IN2012DN01981A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1981DEN2012 2009-09-24 2010-09-22 IN2012DN01981A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27243809P 2009-09-24 2009-09-24
PCT/JP2010/067017 WO2011037271A1 (en) 2009-09-24 2010-09-22 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN01981A true IN2012DN01981A (cg-RX-API-DMAC7.html) 2015-07-24

Family

ID=43796008

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1981DEN2012 IN2012DN01981A (cg-RX-API-DMAC7.html) 2009-09-24 2010-09-22

Country Status (9)

Country Link
US (1) US8617829B2 (cg-RX-API-DMAC7.html)
EP (1) EP2480665A4 (cg-RX-API-DMAC7.html)
JP (1) JP5781504B2 (cg-RX-API-DMAC7.html)
KR (1) KR101809761B1 (cg-RX-API-DMAC7.html)
CN (1) CN102712921B (cg-RX-API-DMAC7.html)
AU (1) AU2010299017B2 (cg-RX-API-DMAC7.html)
CA (1) CA2772230C (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01981A (cg-RX-API-DMAC7.html)
WO (1) WO2011037271A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703785T3 (es) * 2013-04-08 2019-03-12 Regentys Corp Método y composición para tratar una enfermedad inflamatoria intestinal sin colectomía
EP3286218B1 (en) * 2015-04-20 2022-11-30 Consejo Superior de Investigaciones Cientificas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif
EP3543337B1 (en) * 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
EP3795590A4 (en) 2018-05-17 2022-05-04 Astellas Pharma Inc. COMPLEX WITH ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND
US12065503B2 (en) 2018-10-10 2024-08-20 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
JP2003517284A (ja) 1999-04-15 2003-05-27 チルドレンズ メディカル センター コーポレーション 免疫応答を変調する方法及び組成物
JP2003528322A (ja) 2000-03-23 2003-09-24 グラクソ グループ リミテッド オステオポンチンのインヒビターのスクリーニング方法
JP2007106767A (ja) * 2001-04-05 2007-04-26 Meneki Seibutsu Kenkyusho:Kk 抗オステオポンチン抗体およびその用途
MXPA03009052A (es) 2001-04-05 2004-10-15 Immuno Biological Lab Co Ltd Anticuerpo anti-osteopontina y uso del mismo.
JPWO2003027151A1 (ja) 2001-09-25 2005-01-06 株式会社 免疫生物研究所 組換え抗オステオポンチン抗体およびその用途
US20070274993A1 (en) 2003-05-23 2007-11-29 Immuno-Biological Laboratories Co., Ltd. Immunocompetent Cell Activation Inhibitor and Use Thereof
EP2075258B1 (en) * 2006-10-26 2012-06-20 Gene Techno Science Co., Ltd. Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
JP5736176B2 (ja) * 2008-04-24 2015-06-17 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびその使用

Also Published As

Publication number Publication date
WO2011037271A1 (en) 2011-03-31
CA2772230A1 (en) 2011-03-31
US8617829B2 (en) 2013-12-31
KR20120078725A (ko) 2012-07-10
EP2480665A4 (en) 2013-04-03
CN102712921B (zh) 2017-03-01
CA2772230C (en) 2019-01-08
AU2010299017B2 (en) 2014-02-06
EP2480665A1 (en) 2012-08-01
AU2010299017A1 (en) 2012-03-15
JP2013505702A (ja) 2013-02-21
JP5781504B2 (ja) 2015-09-24
CN102712921A (zh) 2012-10-03
KR101809761B1 (ko) 2017-12-15
US20120219503A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
EP2388323A3 (en) Humanized anti-9 integrin antibodies and the uses thereof
IN2012DN01981A (cg-RX-API-DMAC7.html)
NZ594315A (en) Antibody molecules having specificity for human ox40
Relle et al. Genetics and novel aspects of therapies in systemic lupus erythematosus
MY185006A (en) Human antibodies to human tnf-like ligand ia (tl1a)
EA201300418A1 (ru) Антитела к человеческому tweak и варианты их применения
NZ606587A (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
NZ710299A (en) Methods, systems, and software for identifying bio-molecules with interacting components
TN2015000348A1 (en) Antibodies that bind il-23
WO2010128407A8 (en) Anti-il-17f antibodies and methods of use thereof
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
TW200740844A (en) Novel MAdCAM antibodies
EP2037961A4 (en) METHODS OF TREATING AUTOIMMUNE DISORDERS USING MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY
MX2013013329A (es) Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos.
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
NZ604643A (en) S100a4 antibodies and therapeutic uses thereof
IL232169B (en) Antigens obtained from citrullinated 3-3-14 and their uses in the diagnosis of rheumatoid arthritis
IN266863B (cg-RX-API-DMAC7.html)
EA201291345A1 (ru) Цитруллинированные гистоновые пептиды и их применение
HRP20141110T1 (hr) Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo
WO2011158122A3 (en) Anti-human equilibrative nucleoside transporter 1 (hent1) antibodies and methods of use thereof
NZ602906A (en) Novel interferon-alpha-producing bone marrow dendritic cells
JP2011140474A5 (cg-RX-API-DMAC7.html)
WO2017081218A3 (en) Anti-human il-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of il-3, and their use in a method to detect human il-3
WO2011020933A8 (es) Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail